The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

Researchers have found in a new systematic review and meta-analysis that higher levels of environmental pollutants and ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Arcutis is financially strong, with over 30 months of cash runway. The atopic dermatitis market is large and shifting away ...

Spongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with ...